Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Safety and Efficacy of Tyrosine Kinase Inhibitors Against Egfr in Patients With Glioma; a Systematic Review, Meta-Analysis, and Sub-Group Analysis on Glioblastoma Publisher Pubmed



Habibi MA1 ; Ahmadvand MH2 ; Delbari P2, 3 ; Mirjani MS3 ; Zare AH2 ; Mehdizadeh B4 ; Allahdadi A4 ; Ardestani Z4 ; Rad RH5 ; Aliasgary A6 ; Sabet S2 ; Eftekhar MS7 ; Mohammadzadeh I8 ; Hajikarimloo B9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Student Research Committee, Qom University of Medical Sciences, Qom, Iran
  4. 4. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Medicine, Tehran Medical Branch, Islamic Azad University, Tehran, Iran
  6. 6. Student Research Committee of Qom University of Medical Sciences, Qom, Iran
  7. 7. Department of Surgery, School of Medicine, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran
  8. 8. Skull Base Research Center, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  9. 9. Department of Neurological Surgery, University of Virginia, Charlottesville, VA, United States

Source: Journal of Clinical Neuroscience Published:2025


Abstract

Background: Gliomas, particularly glioblastoma (GBM), remain challenging to treat and have a poor prognosis. Tyrosine kinase inhibitors (TKIs) targeting EGFR have shown promise, but their efficacy in gliomas is not well established. This study aimed to systematically review and meta-analyze the safety and efficacy of EGFR TKIs in patients with glioma, specifically for primary and recurrent GBM. Methods: A comprehensive literature search was conducted across PubMed, Embase, Scopus, and Web of Science up to January 1, 2024. Randomized controlled trials and observational studies evaluating TKIs in glioma patients were included. Primary outcomes were overall survival (OS), progression-free survival (PFS), and adverse events. A random-effects meta-analysis was performed to pool results. All statistical analysis was performed using STATA v.17. Results: A total of 2,424 patients from 51 studies were included. The pooled mean OS was 12.68 months (95 % CI: 6.29–19.08) with 1-year and 2-year OS rates of 43 % (95 % CI: 34 %-52 %) and 14 % (95 % CI: 8 %-20 %), respectively. The mean PFS was 9.61 months (95 % CI: 4.83–14.38). The overall response rate was 19 % (95 % CI: 1 %-36 %). Grade ≥ 3 adverse events occurred in 35 % of patients (95 % CI: 13 %-57 %). Subgroup analyses revealed that combination therapies outperformed TKI monotherapy, and some newer TKIs, like vandetanib, showed improved efficacy. Conclusions: TKIs demonstrate modest but meaningful benefits in glioma treatment, particularly when combined with other therapies. While initial survival improvements are observed, long-term outcomes remain challenging. Further research is needed to develop more potent, brain-penetrant TKIs and optimize combination strategies to improve outcomes in glioma patients. © 2025 Elsevier Ltd
Related Docs
View other Related Docs
1. The Safety and Efficacy of Vegfr Tyrosine Kinase Inhibitors for Patients With Gliomas: A Systematic Review, Meta-Analysis, and a Specific Analysis on Glioblastoma, Neurosurgical Review (2025)
2. Autophagy in Cancers Including Brain Tumors: Role of Micrornas, Cell Communication and Signaling (2020)
3. Survival Factors in 1580 Adults With Spinal Ependymoma: Insights From a Multicenter Oncology Database, World Neurosurgery (2024)
4. Computational Prediction of Drug-Drug Interactions Based on Drugs Functional Similarities, Journal of Biomedical Informatics (2017)
5. Chemotherapeutic Effects of Boswellic Acid Against Human Glioblastoma Multiform: A Comprehensive Review, Natural Products Journal (2023)
6. Lipidomics-Driven Drug Discovery and Delivery Strategies in Glioblastoma, Biochimica et Biophysica Acta - Molecular Basis of Disease (2025)
7. Car-Engineered Nk Cells Versus Car T Cells in Treatment of Glioblastoma; Strength and Flaws, Journal of Neuro-Oncology (2025)
8. Genetic Prognostic Factors in Adult Diffuse Gliomas: A 10-Year Experience at a Single Institution, Cancers (2024)
Experts (# of related papers)
View all Related Experts
Hamid Reza Mirzaei (1)
Nima Rezaei (1)
Other Related Docs
9. Are Egfr Monoclonal Antibodies Associated With Clinical Benefits in Patients With Glioma: A Systematic Review, Meta-Analysis, and Specific Analysis on Glioblastoma and Diffuse Intrinsic Pontine Glioma, Neurosurgical Review (2025)